Compare CELC & PRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELC | PRM |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.8B |
| IPO Year | 2017 | 2021 |
| Metric | CELC | PRM |
|---|---|---|
| Price | $53.29 | $27.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $150.85 | $39.33 |
| AVG Volume (30 Days) | 920.9K | ★ 1.1M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.14 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $34.85 |
| Revenue Next Year | $1,921.71 | $10.36 |
| P/E Ratio | ★ N/A | $25.71 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $53.54 | $20.38 |
| 52 Week High | $151.02 | $38.17 |
| Indicator | CELC | PRM |
|---|---|---|
| Relative Strength Index (RSI) | 30.06 | 41.22 |
| Support Level | N/A | $25.43 |
| Resistance Level | $72.76 | $32.32 |
| Average True Range (ATR) | 4.24 | 1.50 |
| MACD | -1.03 | -0.11 |
| Stochastic Oscillator | 0.16 | 11.68 |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Perimeter Group Inc is a provider of industrial products and services that support critical and complex customer missions across a range of niche applications. It comprises six market businesses across two reporting segments: Fire Safety (Perimeter Solutions, Solberg Fire, and Monaco Enterprises) and Specialty Products (PDI, MMT, and IMS). The group prioritizes serving customer needs while driving private-equity-like returns, enabled by its Operational Value Drivers model and decentralized operating structure. Perimeter reinvests in its businesses to strengthen the products and services it provides to customers, and it expects to continue growing organically and through value-creating acquisitions.